Logo image of CMPX

COMPASS THERAPEUTICS INC (CMPX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CMPX - US20454B1044 - Common Stock

5.14 USD
+0.15 (+3.01%)
Last: 12/22/2025, 8:00:00 PM
5.14 USD
0 (0%)
After Hours: 12/22/2025, 8:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CMPX. CMPX was compared to 530 industry peers in the Biotechnology industry. While CMPX has a great health rating, there are worries on its profitability. CMPX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CMPX has reported negative net income.
In the past year CMPX has reported a negative cash flow from operations.
CMPX had negative earnings in each of the past 5 years.
In the past 5 years CMPX always reported negative operating cash flow.
CMPX Yearly Net Income VS EBIT VS OCF VS FCFCMPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

CMPX has a Return On Assets of -21.35%. This is in the better half of the industry: CMPX outperforms 73.96% of its industry peers.
With an excellent Return On Equity value of -23.56%, CMPX belongs to the best of the industry, outperforming 80.57% of the companies in the same industry.
Industry RankSector Rank
ROA -21.35%
ROE -23.56%
ROIC N/A
ROA(3y)-27.3%
ROA(5y)-38.44%
ROE(3y)-29.88%
ROE(5y)-44.45%
ROIC(3y)N/A
ROIC(5y)N/A
CMPX Yearly ROA, ROE, ROICCMPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CMPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPX Yearly Profit, Operating, Gross MarginsCMPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

CMPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CMPX has more shares outstanding
CMPX has more shares outstanding than it did 5 years ago.
CMPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMPX Yearly Shares OutstandingCMPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CMPX Yearly Total Debt VS Total AssetsCMPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 22.36 indicates that CMPX is not in any danger for bankruptcy at the moment.
CMPX has a better Altman-Z score (22.36) than 90.75% of its industry peers.
There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.36
ROIC/WACCN/A
WACC8.8%
CMPX Yearly LT Debt VS Equity VS FCFCMPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

CMPX has a Current Ratio of 17.82. This indicates that CMPX is financially healthy and has no problem in meeting its short term obligations.
CMPX's Current ratio of 17.82 is amongst the best of the industry. CMPX outperforms 94.34% of its industry peers.
A Quick Ratio of 17.82 indicates that CMPX has no problem at all paying its short term obligations.
CMPX's Quick ratio of 17.82 is amongst the best of the industry. CMPX outperforms 94.34% of its industry peers.
Industry RankSector Rank
Current Ratio 17.82
Quick Ratio 17.82
CMPX Yearly Current Assets VS Current LiabilitesCMPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

CMPX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.62%.
EPS 1Y (TTM)-21.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CMPX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.66% yearly.
Based on estimates for the next years, CMPX will show a very strong growth in Revenue. The Revenue will grow by 232.95% on average per year.
EPS Next Y-21.55%
EPS Next 2Y-12.9%
EPS Next 3Y-2.28%
EPS Next 5Y29.66%
Revenue Next Year-100%
Revenue Next 2Y193.91%
Revenue Next 3Y324.64%
Revenue Next 5Y232.95%

3.3 Evolution

CMPX Yearly Revenue VS EstimatesCMPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
CMPX Yearly EPS VS EstimatesCMPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMPX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMPX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPX Price Earnings VS Forward Price EarningsCMPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPX Per share dataCMPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

CMPX's earnings are expected to decrease with -2.28% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.9%
EPS Next 3Y-2.28%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMPX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

COMPASS THERAPEUTICS INC

NASDAQ:CMPX (12/22/2025, 8:00:00 PM)

After market: 5.14 0 (0%)

5.14

+0.15 (+3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners73.97%
Inst Owner Change37.27%
Ins Owners6.62%
Ins Owner Change-0.36%
Market Cap914.20M
Revenue(TTM)850.00K
Net Income(TTM)-49.38M
Analysts88.24
Price Target12.55 (144.16%)
Short Float %12.24%
Short Ratio9.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.34%
Min EPS beat(2)-12.3%
Max EPS beat(2)42.98%
EPS beat(4)1
Avg EPS beat(4)3.69%
Min EPS beat(4)-12.3%
Max EPS beat(4)42.98%
EPS beat(8)3
Avg EPS beat(8)7.29%
EPS beat(12)6
Avg EPS beat(12)11.28%
EPS beat(16)8
Avg EPS beat(16)-0.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.66%
PT rev (3m)-6.76%
EPS NQ rev (1m)-0.63%
EPS NQ rev (3m)30.76%
EPS NY rev (1m)18.44%
EPS NY rev (3m)17.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1075.53
P/FCF N/A
P/OCF N/A
P/B 4.36
P/tB 4.36
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS1.18
TBVpS1.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.35%
ROE -23.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.3%
ROA(5y)-38.44%
ROE(3y)-29.88%
ROE(5y)-44.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.01%
Cap/Sales 2.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.82
Quick Ratio 17.82
Altman-Z 22.36
F-Score3
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)12.9%
Cap/Depr(5y)74.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-21.55%
EPS Next 2Y-12.9%
EPS Next 3Y-2.28%
EPS Next 5Y29.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y193.91%
Revenue Next 3Y324.64%
Revenue Next 5Y232.95%
EBIT growth 1Y-12.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.86%
EBIT Next 3Y-10.13%
EBIT Next 5Y20.19%
FCF growth 1Y-15.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.78%
OCF growth 3YN/A
OCF growth 5YN/A

COMPASS THERAPEUTICS INC / CMPX FAQ

What is the fundamental rating for CMPX stock?

ChartMill assigns a fundamental rating of 3 / 10 to CMPX.


What is the valuation status of COMPASS THERAPEUTICS INC (CMPX) stock?

ChartMill assigns a valuation rating of 0 / 10 to COMPASS THERAPEUTICS INC (CMPX). This can be considered as Overvalued.


What is the profitability of CMPX stock?

COMPASS THERAPEUTICS INC (CMPX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for COMPASS THERAPEUTICS INC?

The Earnings per Share (EPS) of COMPASS THERAPEUTICS INC (CMPX) is expected to decline by -21.55% in the next year.